GRI Bio (NASDAQ: GRI) to Present at Virtual Investor Pitch

GRI Bio, Inc., a biotechnology firm specializing in innovative treatments for inflammatory, fibrotic, and autoimmune diseases, has announced its participation in the Virtual Investor Pitch Conference on June 18, 2024, at 11:00 AM ET. During this event, Marc Hertz, PhD, the company's Chief Executive Officer, will present an "elevator pitch" and discuss the company's upcoming milestones. This live webcast will also provide an opportunity for investors and other interested parties to submit questions, which will be addressed during the presentation as time allows.

The live video webcast of the presentation will be accessible via the Events page in the Investors section of GRI Bio's website, gribio.com. For those unable to attend the live event, a replay of the webcast will be available two hours after the presentation and will remain accessible for 90 days.

GRI Bio is a clinical-stage biopharmaceutical company committed to transforming the treatment of inflammatory, fibrotic, and autoimmune diseases. Their focus is on developing therapies that modulate Natural Killer T (NKT) cells, which are crucial regulators in the early stages of the inflammatory process. By targeting NKT cells, GRI Bio aims to interrupt disease progression and help restore the immune system to a balanced state.

NKT cells are a specialized subset of T cells that possess characteristics of both Natural Killer (NK) cells and T cells, thus acting as a bridge between the innate and adaptive immune systems. Specifically, Type 1 invariant (iNKT) cells play a vital role in driving the injury, inflammation, and fibrosis seen in various inflammatory and fibrotic conditions. GRI Bio's leading candidate, GRI-0621, is an oral therapeutic designed to inhibit iNKT cell activity and is being developed for the treatment of idiopathic pulmonary fibrosis—a serious disease for which there are limited effective treatments.

Beyond GRI-0621, GRI Bio is also working on a pipeline of novel type 2 NKT agonists aimed at treating systemic lupus erythematosus, another autoimmune condition. The company boasts a library of over 500 proprietary compounds, which enables the continuous development of new therapeutic candidates to expand its pipeline.

This event marks an important opportunity for GRI Bio to communicate its strategic vision and progress to potential investors, showcasing its approach to tackling diseases that currently have significant unmet medical needs.